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A B ST R AC T  
 
Coronaviruses, a large family of single-stranded RNA viruses, can infect humans and animals, and 
can cause neurological, gastrointestinal and hepatic diseases as well as causing various lung diseases, 
including pneumonia, with shortness of breath, cough and fever. At the end of December 2019, a 
group of health authorities reported unidentified cases of pneumonia in a seafood market in Wuhan, 
China. The World Health Organization (WHO) used term 2019 novel coronavirus (COVID-19) to 
refer to a coronavirus that affected the lower respiratory tract of patients with pneumonia in Wuhan, 
China on 29 December and the WHO announced that the official name of the 2019 novel coronavirus 
was coronavirus disease (COVID-19). COVID-19 is seen in many countries around the World and 
has been accepted as a pandemic by WHO. It is defined as a suspicious case with fever, sore throat, 
cough, and people with a history of traveling to China or some parts of the country, or someone who 
contact with a patient who has a history of travel in China or contact with a confirmed COVID-19 
infection patient. Currently, there is no proven vaccine or antiviral therapy that can be used against 
animal or human coronavirus. To control the outbreak, the drugs must be developed as soon as 
possible. Various drugs have been used in the treatment of COVID-19 and the main ones are 
chloroquine, remdesivir, lopinavir/ritonavir, oseltamivir, favipiravir. Since the virus affects the whole 
World, vaccines and/or new curative antiviral drugs are needed to end the pandemic. For this purpose, 
large-scale observational studies are needed. 
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Introduction 
Coronaviruses, a large family of single-
stranded RNA viruses, can infect humans and 
animals, and can cause neurological, 
gastrointestinal and hepatic diseases as well as 
causing various lung diseases, including 
pneumonia, with shortness of breath, cough and 
fever [1, 2]. Four coronavirus species called 
HKU1, NL63, 229E, OC43 are in circulation in 
humans and are generally cause mild 
respiratory diseases [3].  
In the last 20 years, 2 violent events occurred 
with the transition of betacoronaviruses from 
animals to humans. The first incident was in 
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2002. A new genus of beta coronavirus passed 
on to people using palm civet cats as hosts and 
bats as intermediate hosts in Guangdong 
province in China. This virus, called severe 
acute respiratory syndrome (SARS) 
coronavirus, affected 8422 people in China and 
Hong Kong and 916 people died (mortality rate 
was 11%) [4]. Almost 10 years later, in 2012, 
the Middle East respiratory syndrome 
coronavirus (MERS-CoV) appeared in Saudi 
Arabia, using dromedary camels as hosts, bats 
as intermediate hosts, 2494 people affected and 
858 people died (mortality rate was 34%) [5]. 
At the end of December 2019, a group of health 
authorities reported unidentified cases of 
pneumonia in a seafood market in Wuhan, 
China [6]. Although most of the early infected 
patients were seen in the Huanan seafood 
market in Wuhan, China, 13 of 141 cases were 
not affiliated with the market [7]. Although it 
started in the first patient on 1 December 2019, 
its relationship with seafood market was not 
reported. There was no epidemiological link 
between the first case and the next ones. 
Probably the first virus came to the market and 
spread from there [8]. 
The World Health Organization (WHO) used 
term 2019 novel coronavirus (COVID-19) to 
refer to a coronavirus that affected the lower 
respiratory tract of patients with pneumonia in 
Wuhan, China on 29 December and the WHO 
announced that the official name of the 2019 
novel coronavirus was coronavirus disease 
(COVID-19) [9]. The current reference name 
for the virus is severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2) and at 
the end of December 2019, this virus was 
blamed as the cause of pneumonia cases 
occurring in Wuhan, China [6]. COVID-19 has 
been declared as a Public Health Emergency of 
International concern by the WHO [10].  
COVID-19 is seen in many countries around 
the World and has been accepted as a pandemic 
by WHO. With this review, we aim to explain 
general information about COVID-19, its 
diagnosis, laboratory and radiological findings, 
diagnosis and treatment methods. 
 
Clinical findings and symptoms 
Examining the current epidemiological study, 
most individuals had a close contact history 
with a patient with COVID-19 or a recent travel 
history to Wuhan or Hubei province in China 
[11]. The symptoms of COVID-19 infection 
were not specific. The most common symptoms 
were fever, weakness, fatigue and dry cough. 
Some patients also had headache and/or muscle 
pain, but no upper respiratory tract symptoms 
[11]. Diarrhea was reported with a frequency of 
10.6% in SARS and 30% in MERS [12]. More 
than half of the patients developed shortness of 
breath. The median duration of the appearance 
of dyspnea from the beginning of the disease 
was 8 days [7]. If the disease could not 
controlled, patients with COVID-19 may 
develop acute respiratory distress syndrome 
(ARDS), followed by septic shock, metabolic 
acidosis and coagulation dysfunction [11]. 
Although pneumonia was also seen in patients 
infected with COVID-19, few had pleuritic 
chest pain [13].  
Patients were divided into 3 groups as mild, 
severe and critical, depending on the severity of 
the symptoms (Table-1). Mild patients had non-
pneumonia or mild pneumonia. Severe patients 
had several clinical findings, including 
dyspnea, respiratory  frequency ≥ 30/min, blood 
oxygen saturation ≤ 93%, partial pressure of 
arterial oxygen to fraction of inspired oxygen 
ratio < 300, and/or lung infiltrates >50% within 
24 to 48 hours. Critical patients had severe 
conditions, such as respiratory failure, septic 
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shock, and/or multiple organ dysfunction or 
failure [14].  
 
Table 1. Clinical symptoms associated with 
COVID-19. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Laboratory findings 
Among the laboratory findings, leukopenia and 
lymphopenia were the most common [7, 15, 
16]. Lymphopenia was the most important 
laboratory finding in COVID-19 infection. 
While lactate dehydrogenase (LDH) and 
creatine kinase (CPK) increased in all patients, 
alanine aminotransferase (ALT) or aspartate 
aminotransferase (AST) was found to be high 
in half of the patients. In most patients, 
myocardial tests were abnormal, with elevated 
CPK and LDH. In most patients, procalcitonine 
was normal, while C - reactive protein (CRP) 
was above the normal range. D-dimer was 
elevated in one third of the patients [7, 13, 15, 
16].  
In a study investigating cytokines in the serum 
of COVID-19 patients. Interleukin (IL)1B, 
IL1RA, IL7, IL8, IL9, IL10, basic in plasma 
fibroblast growth factor (FGF), granulocyte 
colony stimulating factor (GCSF), granulocyte-
macrophage colony stimulating factor 
(GMCSF), interferon-gamma (IFNγ), induced 
protein-10 (IP10), monocyte chemoattractant 
protein-1 (MCP1), macrophage inflammatory 
protein-1A (MIP1A), macrophage 
inflammatory protein-1B (MIP1B), platelet-
derived growth factor (PDGF), tumor necrotic 
factor alpha (TNFα) and vascular endothelial 
growth factor (VEGF) concentrations were 
higher than healthy adults. Plasma levels of 
IL5, IL12 p70, IL15, Eotaxin and RANTES 
(regulated upon activation, normal T cell 
expressed and secreted [also known as CCL5]) 
were similar to that of healthy individuals and 
patients. When the serum plasma of patients 
with and without intensive care unit is 
compared, IL2, IL7, IL10, GCSF, IP10, 
mitochondrial pyruvate carrier 1 (MPC1), 
MIP1A, and TNFα levels were higher in 
intensive care patients than in non-intensive 
care patients [7].  
 
Radiological findings 
Radiological images of patients infected with 
COVID-19 are quite diverse and can be rapidly 
progressed [17-19]. At least two-thirds of 
patients had at least two lobes affected. At least 
5 lobes were effected in half of the patients. The 
most common manifestations in computerize 
tomography (CT) images are irregular ground 
glass opacities (GGO) and patchy 
consolidations, especially in the middle and 
outer zones of the lung [19, 20]. 
In one study, radiological findings was divided 
into 4 stages according to CT images of patients 
infected with COVID-19. In the early stage, 
unilateral or bilateral GGO in the lower lobes of 
the lung was the main radiological findings. In 
the progressive stage, diffuse and bilateral 
GGO and consolidation in more than 2 lobes 
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were the main findings. In the peak stage, 
diffuse GGO and consolidation began to 
become more evident. In the absorption stage, 
wide GGO could be observed and consolidation 
was gradually absorbed [20]. 
 
Pathological findings 
Pathological findings of COVID-19 were rare. 
In one study, primary finding in biopsy of a 50-
year-old man with cardiac arrest due to 
respiratory failure died after 14 days were 
cellular fibromyxoid exudates, and bilateral 
diffuse alveolar hemorrhage areas and 
infiltrated areas where lymphocytes 
predominate [21]. Multinucleated syncytial 
cells with atypical enlarged pneumocytes 
characterized by large nuclei, amphophilic 
granular cytoplasm, and prominent nucleoli 
were identified in the intraalveolar spaces, 
showing viral cytopathic-like changes. No 
obvious intranuclear or intracytoplasmic viral 
inclusions were identified. These pathological 
features show great similarities to SARS-CoV 
and MERS-CoV infection [22-24]. 
 
Diagnosis 
It is defined as a suspicious case with fever, sore 
throat, cough, people with a history of traveling 
to China or some parts of the country, or 
someone who contact with a patient who has a 
history of travel in China or  contact with a 
confirmed COVID-19 infection patient [25]. 
1. Physical examination 
Positive results may not be achieved in patients 
with mild patients. Severe patients may have 
shortness of breath, rales in lungs, weakened 
breath sounds, dullness in percussion, and 
increased or decreased tactile speech tumor [12, 
13]. 
2. Laboratory tests 
According to Koch’s proposals, the gold 
standard is virus isolation in the laboratory 
diagnosis of the virus [26]. Viral nucleic acids 
can be useful in the early diagnosis of the 
disease, which is the most important thing. The 
nucleic acid in the RNA sequence of SARS-
CoV-2 was aimed to be detected and the full 
gene sequence of SARS-CoV-2 was obtained. 
For this purpose, samples were taken from the 
upper respiratory tract (throat stick / 
nasopharyngeal rod / sputum sample / 
endotracheal sample / aspirates and 
bronchoalveolar lavage) and the diagnosis of 
SARS-CoV-2 infection was made by real-time 
PCR [25-27]. 
Other laboratory examinations are generally not 
specific. The white cell count is usually low or 
normal. There may be lymphopenia, and a 
lymphocyte count of < 1000 can be a sign of 
serious disease. Platelet count is usually low or 
normal. CRP and erythrocyte sedimentation 
rate (ESR) is generally high, but procalcitonin 
levels are usually normal. AST, ALT, 
creatinine, CPK, LDH, D-Dimer, prothrombin 
time may increase and these values are 
associated with severe disease [25]. 
3. CT examination 
The chest X-ray usually shows infiltrated areas 
in the lung, but the x-ray may be normal in the 
early stages of the disease. CT is more sensitive 
and specific in demonstrating GGO, infiltrated 
areas and lower lobe consolidations in the lung. 
CT is also normal in asymptomatic patients / 
patients without lower respiratory tract 
involvement. In fact, in COVID-19 patients 
whose molecular tests are negative, abnormal 
findings can be detected in CT. Also, positivity 
can be detected in these patients by repeating 
molecular tests [25].  
 
Treatment 
Currently, there is no proven vaccine or 
antiviral therapy that can be used against animal 
or human coronaviruses. To control the 
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outbreak, the drugs must be developed as soon 
as possible. WHO stated that a vaccine for 
SARS-CoV-2 could be available within 18 
months [28]. The most important step in the 
clinical management of the disease is largely 
symptomatic therapy. Intensive care unit may 
be required for severe patients and those with 
organ involvement [29]. 
Various drugs have been used in the treatment 
of COVID-19 and the main ones are as follows: 
Chloroquine  
Chloroquine is a drug with high potential to 
treat COVID-19 infection. Chloroquine has 
been used for many years in malaria treatment 
[30]. Several possible mechanisms for 
chloroquine treatment have been investigated. 
Chloroquine can replace intracellular pH by 
following the replication steps of various 
viruses. And with this mechanism, chloroquine 
can have potential positive effects in treating 
SARS-CoV-2 infection [31, 32]. One study 
found that chloroquine prevents replication of 
the new type of coronavirus [33]. Gao et al. 
found that chloroquine prevents pneumonia 
exacerbation, improves lung images and allows 
negative transformation of the virus [34].  
Remdesivir 
Remdesivir (GS-5734) is a 1′-cyano-substituted 
adenosine nucleotide analog prodrug [35]. 
Remdesivir has been reported to treat a first 
case of COVID-19 in America [36]. A study 
have shown that remdesivir gives good results 
in COVID-19 patients and treats the disease 
[33]. In addition, another study stated that 
remdesivir may be the best treatment option in 
COVID-19 [37].  
Lopinavir/Ritonavir  
Lopinavir is a protease inhibitor used in HIV 
treatment, with ritonavir as a booster. Lopinavir 
or lopinavir/ritonavir showed anti-coronavirus 
activity in in-vitro studies. IFN-α has broad-
spectrum antiviral effect, it is an agent used in 
the treatment of hepatitis-B virus. IFN-α (5 
million U bid inh) and lopinavir/ritonavir (400 
mg/100 mg bid po) combine therapy are 
recommended as antiviral therapy. This 
treatment used to treat SARS [38]. This 
treatment is also recommended for SARS-CoV-
2 [39]. 
Oseltamivir 
Oseltamivir is a neuraminidase enzyme 
inhibitor and is used to treat influenza [40]. In a 
42-year old male patient, COVID-19 
pneumonia was detected in January 2020 in 
Wuhan province, China. CT images were 
improved after treatment with ganciclovir and 
oseltamivir [41]. In many studies, oseltamivir 
was used in combination with various antiviral 
drugs in patients infected with COVID-19, no 
positive results have been encountered [7, 13, 
16].  
Favipiravir 
Favipiravir is a new type of RNA-dependent 
RNA polymerase inhibitor. In addition to its 
anti-influenza virus activity, favipiravir is 
capable of blocking the replication of flavi-, 
alpha-, filo-, bunya-, arena-, noro-, and other 
RNA viruses [42]. A study conducted in China 
in February 2020 provided positive results 
about favipiravir. One group was given 
favipiravir and the other group was given 
lopinavir/ritonavir. The third group was the 
control group. Compared to the groups, better 
antiviral efficacy was observed in the group 
treated with favipiravir, and no significant 
adverse effects were observed in this group. 
Significantly more negative effects were 
encountered in the group treated with 
lopinavir/ritonavir [43].  
In another study, in COVID-19 patients who 
did not receive antiviral therapy before, 
favipiravir was found to be an effective 
treatment when anti-viral side effects were 
excluded, since it provided improvement in the 
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clinic in 7 days, effectively reducing fever and 
cough [44].  
Comments 
As a result, 2019 novel coronavirus is a new 
virus and its mechanism and treatment is not 
fully known. Since the disease especially 
affects the airways and lungs, patients 
complained of cough and shortness of breath 
and some patients died from the ARDS. 
Although the disease occurs in China, it affects 
the whole world, the pandemic table is heavy in 
many countries, and people, countries are 
negatively affected both socially and 
economically and their health policies are 
insufficient. In studies conducted, patients with 
older age, chronic diseases such as diabetes 
mellitus, hypertension, chronic obstructive 
pulmonary disease (COPD), cancer, kidney 
failure, heart failure were evaluated as risk 
groups [45-47]. That’s why people over 65 
years old, people with chronic diseases such as 
diabetes mellitus, hypertension, cancer, heart 
failure, kidney failure and those who use 
immunosuppressive drugs need to protect 
themselves more. 
As of 29.03.2020, the number of cases 
worldwide has reached 665.616, the number of 
deaths has reached 30.857, and the number of 
patients recovering from the disease has 
reached 141.746. The number of cases in China 
has reached 82.061, the number of dead has 
reached 3182. The number of cases in Italy has 
reached 92.472 and the number of dead has 
reached 10.023. The number of cases in United 
States has reached 124.686 and the number of 
dead has reached 2.192. The number of cases in 
Spain has reached 73.235 and the number of 
dead has reached 5.982. The number of cases in 
Turkey has reached 7402 and the number of 
dead has reached 108 people [48]. According to 
these data, as of 29 March 2020 date, SARS-
CoV-2 mortality is 4.63% all over the World, 
%4.03 in China, 10.84% in Italy, 8.17% in 
Spain, 1.76% in United States and 1.46% in 
Turkey (Table 2). Although the virus first 
appeared in China [7] Italy has become the new 
center of the virus due to the dramatic increase 
in the number of cases and deaths in Italy.  
 
Table 2. As of March 29, 2020, SARS-CoV-2 
confirmed cases, number of deaths, mortality rate 
(%) in some countries.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In conclusion, since the virus affects the whole 
World, vaccines and/or new curative antiviral 
drugs are needed to end the pandemic. For this 
purpose, large-scale observational studies are 
needed. 
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